0.00Open1.38Pre Close0 Volume0 Open Interest3.00Strike Price0.00Turnover0.01%IV-18.16%PremiumJan 17, 2025Expiry Date1.63Intrinsic Value100Multiplier-6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-1.0000Delta0.0000Gamma0.99Leverage Ratio0.0000Theta0.0000Rho-0.99Eff Leverage0.0000Vega
Coherus BioSciences Stock Discussion
📊⚡️📊
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Wednesday, 22nd January at 7:00 am
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate –
– Antitumor activity was observed across both viral and non-viral etiologies –
– Data support continued...
$Coherus BioSciences (CHRS.US)$
No comment yet